Evidence map›Paper›PMID 27778251›Full record

ReviewCurrent diabetes reports2016

Biomarkers of Diabetic Retinopathy.

Daniel Shu Wei Ting, Kara-Anne Tan, Val Phua, Gavin Siew Wei Tan, Chee Wai Wong, Tien Yin Wong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Metabolomics in Diabetic Retinopathy: A Systematic Review.Investigative ophthalmology & visual science · 2021
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Advanced CNN Deep Learning Model for Diabetic Retinopathy Classification.Journal of biomedical physics & engineering · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Daniel Shu Wei TingSingapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore.
Kara-Anne TanSingapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore.
Val PhuaSingapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore.
Gavin Siew Wei TanSingapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore.
Chee Wai WongSingapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore.
Tien Yin WongSingapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore. tien_yin_wong@nuhs.edu.sg.
Singapore National Eye Center · SGDuke-NUS Medical School · SGNational University of Singapore · SGSingapore Eye Research Institute · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR), a leading cause of acquired vision loss, is a microvascular complication of diabetes. While traditional risk factors for diabetic retinopathy including longer duration of diabetes, poor blood glucose control, and dyslipidemia are helpful in stratifying patient's risk for developing retinopathy, many patients without these traditional risk factors develop DR; furthermore, there are persons with long diabetes duration who do not develop DR. Thus, identifying biomarkers to predict DR or to determine therapeutic response is important. A biomarker can be defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Incorporation of biomarkers into risk stratification of persons with diabetes would likely aid in early diagnosis and guide treatment methods for those with DR or with worsening DR. Systemic biomarkers of DR include serum measures including genomic, proteomic, and metabolomics biomarkers. Ocular biomarkers including tears and vitreous and retinal vascular structural changes have also been studied extensively to prognosticate the risk of DR development. The current studies on biomarkers are limited by the need for larger sample sizes, cross-validation in different populations and ethnic groups, and time-efficient and cost-effective analytical techniques. Future research is important to explore novel DR biomarkers that are non-invasive, rapid, economical, and accurate to help reduce the incidence and progression of DR in people with diabetes.

Indexed as

BiomarkersDiabetic RetinopathyEarly DiagnosisElectroretinographyHumansMetabolomicsMicroRNAsProteomicsRisk FactorsTomography, Optical CoherenceBiomarkersMicroRNAsBiomarkersDiabetic retinopathyMetabolomicsProteomicSerumTearVitreous

Identifiers

PMID27778251
OpenAlexW2533805916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.